The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
Khang
Peter
P
UCLA Multi-campus Program in Geriatric Medicine, Geffen School of Medicine, Los Angeles, CA, USA.
Weintraub
Nancy
N
Espinoza
Randall T
RT
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000191:economics*; D002219:Carbamates / Q000191:economics / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077265:Donepezil; D005702:Galantamine / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D007189:Indans / Q000191:economics / Q000627:therapeutic use; D008134:Long-Term Care / Q000592:standards; D018696:Neuroprotective Agents / Q000191:economics / Q000627:therapeutic use; D048448:Phenylcarbamates; D010880:Piperidines / Q000191:economics / Q000627:therapeutic use; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D000068836:Rivastigmine; D016896:Treatment Outcome; D014481:United States
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil; D000068836:Rivastigmine